Stock analysts at StockNews.com started coverage on shares of Oragenics (NYSE:OGEN – Get Free Report) in a research note issued on Wednesday. The brokerage set a “sell” rating on the stock.
Oragenics Stock Down 2.8 %
OGEN opened at $1.06 on Wednesday. The stock has a market capitalization of $4.75 million, a PE ratio of -0.11 and a beta of 0.31. The company’s fifty day moving average is $1.78. Oragenics has a fifty-two week low of $1.02 and a fifty-two week high of $7.74.
Oragenics (NYSE:OGEN – Get Free Report) last issued its quarterly earnings data on Friday, March 29th. The company reported ($5.48) EPS for the quarter.
About Oragenics
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Further Reading
- Five stocks we like better than Oragenics
- How to Read Stock Charts for Beginners
- Hasbro’s Management Made All the Right Calls This Quarter
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- About the Markup Calculator
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.
